Ionis Pharmaceuticals Inc. (IONS) Fundamentals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
SHARE INFORMATION
Market Cap$ 6,290,840,100
Shares Outstanding141,941,338
Float119,890,304
Percent Float84.46%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 810,456,000
Latest Fiscal EPS$ -0.19
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions765
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months9,410,841
Institutional Holdings Percent163.0%
Institutional Sold Previous 3 Months15,451,230
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months252,260
Insider Holdings Percent0.7
Insider Sold Previous 3 Months97,596
Insider Shares Owned995,757
TRADING INFO
52 Week High$ 46.15
52 Week Low$ 25.04
52 Week High Change$ 14.73
21 Day Moving Average$ 41.1419
21 Day Extended Moving Average$ 41.8448
50 Day Moving Average$ 38.5238
50 Day Extended Moving Average$ 39.7088
200 Day Moving Average$ 35.0675
200 Day Extended Moving Average$ 37.3604
10 Day Average Volume1,284,742
20 Day Average Volume944,999
30 Day Average Volume931,598
50 Day Average Volume942,097
Alpha-0.007964
Beta0.6953
Standard Deviation0.095047
R20.133878
7 Day Price Change$ 0.06
7 Day Percent Change0.14%
21 Day Price Change$ 6.27
21 Day Percent Change16.48%
30 Day Price Change$ 5.01
30 Day Percent Change12.74%
Month to Date Price Change$ 6.76
Month to Date Percent Change18.0%
Quarter to Date Price Change$ 7.30
Quarter to Date Percent Change19.72%
180 Day Price Change$ 10.92
180 Day Percent Change32.69%
200 Day Price Change$ 12.64
200 Day Percent Change39.9%
Year to Date Price Change$ 13.89
Year to Date Percent Change45.65%

Ionis Pharmaceuticals Inc. (IONS) Key Ratios

PROFITABILITY
EBIT Margin-2.7%
EBITDA Margin-0.3%
Pre-Tax Profit Margin8.1%
Profit Margin Count-4.82%
Gross Margin98.3%
Profit Margin TOT-4.82%
INCOME STATEMENTS
Revenue$ 848,809,000
Revenue Per Share$ 5.98
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book10.60
Total Debt To Equity2.00
Int Coverage-6.80
Current Ratio8.20
Leverage Ratio3.80
Quick Ratio7.60
Long Term Debt To Capital0.67
VALUATION MEASURES
PE Ratio-246.70
Enterprise Value$ 5,530,187,820
Price to Sales7.4114
Price to Free Cash77.10
PE High Last 5 Years1,196.20
Price To Book10.10
Price To Cash Flow63.90
PE Low Last 5 Years-51.80
Price to Tangible Book10.60
MANAGEMENT EFFECTIVENESS
Receivables Turnover22.20
Invoice Turnover0.70
Assets Turnover0.40
Return Assets-1.21
Return on Equity-4.94
Return on Capital-1.42

Ionis Pharmaceuticals Inc. (IONS) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOBrett P. Monia
Emplyoees660
Last AuditUE
CIK0000874015
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address2855 Gazelle Court
Carlsbad, CA 92010
Websitehttps://www.ionispharma.com
Facsimile+1 760 268-4922
Telephone+1 760 931-9200
EmailWWalke@ionisph.com


Your Recent History
NASDAQ
IONS
Ionis Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.